About Zinc finger protein 181
Zinc finger protein 181 (ZNF181) is a protein
from Homo sapiens identified by UniProt accession
Q2M3W8, 571 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Zinc finger protein 181 |
|---|
| UniProt accession | Q2M3W8 |
|---|
| Gene | ZNF181 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 571 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (6)
Diseases linked to this target (Open Targets).
- bone density · score 0.09
- urate measurement · score 0.09
- DNA methylation · score 0.07
- meningeal tuberculosis · score 0.00
- relapsing-remitting multiple sclerosis · score 0.00
- acute myeloid leukemia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q2M3W8-F1 | alphafold | PREDICTED | 63.92 | — |
Amino-acid sequence (571 residues)
MPQVTFNDVA IDFTHEEWGW LSSAQRDLYK DVMVQNYENL VSVAGLSVTK PYVITLLEDG KEPWMMEKKL SKGMIPDWES RWENKELSTK KDNYDEDSPQ TVIIEKVVKQ SYEFSNSKKN LEYIEKLEGK HGSQVDHFRP AILTSRESPT ADSVYKYNIF RSTFHSKSTL SEPQKISAEG NSHKYDILKK NLPKKSVIKN EKVNGGKKLL NSNKSGAAFS QGKSLTLPQT CNREKIYTCS ECGKAFGKQS ILNRHWRIHT GEKPYECREC GKTFSHGSSL TRHLISHSGE KPYKCIECGK AFSHVSSLTN HQSTHTGEKP YECMNCGKSF SRVSHLIEHL RIHTQEKLYE CRICGKAFIH RSSLIHHQKI HTGEKPYECR ECGKAFCCSS HLTRHQRIHT MEKQYECNKC LKVFSSLSFL VQHQSIHTEE KPFECQKCRK SFNQLESLNM HLRNHIRLKP YECSICGKAF SHRSSLLQHH RIHTGEKPYE CIKCGKTFSC SSNLTVHQRI HTGEKPYKCN ECGKAFSKGS NLTAHQRVHN GEKPNSVVSV EKPLDYMNHY TCEKSYRRET V
Explore Zinc finger protein 181 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets